Crestchem Ltd. Announces FY26 Results and Recommends 15% Final Dividend
Crestchem Ltd., following its Board meeting on May 29, 2026, has released its Standalone and Consolidated Financial Results for the quarter and full year ending March 31, 2026. The company also recommended a final dividend of Rs. 1.50 per equity share (Face Value Rs. 10), subject to shareholder approval at the upcoming Annual General Meeting.The Board meeting approved the financial results and took note of several key corporate decisions, including the formation of a new subsidiary and the reappointment and remuneration of senior management members.
Financial Performance Highlights
The company operates within one business segment: Nutrition-Chemical Industries. The audited standalone results provide a detailed view of the financial standing for the quarter ending March 31, 2026, and the full year ended March 31, 2026.Key figures from the Standalone Financials (in Rs. in Lacs):
| Particular | Quarter Ended 31.03.2026 | Year Ended 31.03.2026 |
|---|---|---|
| Revenue from Operations | 1,022.53 | - |
| Total Income (a+b) | 20.37 | 65.88 |
| Total Expenses | 1,042.91 | 3,026.62 |
| Profit before Tax | 885.16 | 2,650.88 |
| Total Comprehensive Income | 109.98 | 270.96 |
| Earnings per Equity Share (Basic/Diluted) | 3.67 | 9.03 |
The Consolidated Financials for the period show:
| Particular | Quarter Ended 31.03.2026 | Year Ended 31.03.2026 |
|---|---|---|
| Revenue from Operations | 1,022.53 | 2,960.74 |
| Total Income (a+b) | 20.37 | 65.88 |
| Total Expenses | 885.16 | 2,650.88 |
| Profit before Tax | 157.75 | 375.75 |
| Total Comprehensive Income | 109.98 | 270.96 |
| Earnings per Equity Share (Basic/Diluted) | 3.67 | 9.03 |
Balance Sheet Snapshot
The company's balance sheet as of March 31, 2026, shows total assets of Rs. 1,628.92 Lacs, up from Rs. 1,054.48 Lacs in the previous year (in Rs. Lacs). The equity section reported Equity share capital at Rs. 300.00 Lacs, while Other equity stood at Rs. 688.55 Lacs.Corporate Decisions and Management Appointments
The Board of Directors made several key appointments and strategic approvals:- Dividend Recommendation: A Final Dividend of Rs. 1.50 per Equity Share (15%) was recommended for the financial year 2025-26, subject to shareholder approval.
- Key Appointments: The Board approved the reappointment and remuneration of Mr. Dipak Narendraprasad Patel, Mrs. Parul Dipak Patel, and Mrs. Tansi Nirmit Patel for a five-year period under Section 188 of the Companies Act, 2013.
- Subsidiary Investment: Approval was granted for investment in OLEO BIOSCIENCES PRIVATE LIMITED (CIN: U20110KA2026PTC218609) not exceeding Rs. 2.25 Crores through methods including loan, intercorporate loans, or Equity Share Capital.
Subsidiary Operations
The Board noted the formation of OLEO BIOSCIENCES PRIVATE LIMITED in Bangalore, Karnataka, incorporated on March 31, 2026. The subsidiary has not commenced commercial operations during the financial year ended 2026, and no significant financial transactions were carried out, except for recognizing subscription money receivable/payable in the respective financial statements.Cash Flow Summary (Year Ended March 31, 2026)
The company reported net cash used in operating activities at Rs. 359.22 Lacs. Net cash from investing activities stood at a deficit of Rs. 374.76 Lacs, largely due to investment in Fixed Deposits (Rs. 440.48 Lacs).| Cash Flow Activity | Amount (Rs. in Lacs) |
|---|---|
| Net cash used in operating activities (A) | 359.22 |
| Net cash from investing activities (B) | (374.76) |
| Net cash used in financing activities (C) | (17.08) |
| Net Increase/(Decrease) in Cash and Cash Equivalents (A+B+C) | (32.63) |
Stock Price Movement
Crestchem Ltd shares settled on Friday at ₹127.25, registering a 3.60% decline. The stock navigated an intraday range that stretched from the low of ₹125.40 to its high of ₹132.00.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.